168 related articles for article (PubMed ID: 32305493)
1. Glycogen synthase kinase-3: The missing link to aberrant circuit function in disorders of cognitive dysfunction?
Manduca JD; Thériault RK; Perreault ML
Pharmacol Res; 2020 Jul; 157():104819. PubMed ID: 32305493
[TBL] [Abstract][Full Text] [Related]
2. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia.
Cole AR
FEBS J; 2013 Nov; 280(21):5213-27. PubMed ID: 23796137
[TBL] [Abstract][Full Text] [Related]
4. Is glycogen synthase kinase-3 a central modulator in mood regulation?
Li X; Jope RS
Neuropsychopharmacology; 2010 Oct; 35(11):2143-54. PubMed ID: 20668436
[TBL] [Abstract][Full Text] [Related]
5. [Role of glycogen synthase kinase-3β in the pathogenesis of mental disorders].
Ivanova SA; Losenkov IS; Bokhan NA
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(6):93-100. PubMed ID: 25075421
[TBL] [Abstract][Full Text] [Related]
6. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.
Medina M; Avila J
Curr Pharm Des; 2010; 16(25):2790-8. PubMed ID: 20698823
[TBL] [Abstract][Full Text] [Related]
7. GSK-3 inhibitors for Alzheimer's disease.
Avila J; Hernández F
Expert Rev Neurother; 2007 Nov; 7(11):1527-33. PubMed ID: 17997701
[TBL] [Abstract][Full Text] [Related]
8. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders.
Gould TD; Picchini AM; Einat H; Manji HK
Curr Drug Targets; 2006 Nov; 7(11):1399-409. PubMed ID: 17100580
[TBL] [Abstract][Full Text] [Related]
9. Schizophrenia as a GSK-3 dysregulation disorder.
Lovestone S; Killick R; Di Forti M; Murray R
Trends Neurosci; 2007 Apr; 30(4):142-9. PubMed ID: 17324475
[TBL] [Abstract][Full Text] [Related]
10. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
Gould TD; Manji HK
Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
[TBL] [Abstract][Full Text] [Related]
11. Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications.
Gould TD
Expert Opin Ther Targets; 2006 Jun; 10(3):377-92. PubMed ID: 16706678
[TBL] [Abstract][Full Text] [Related]
12. [Schizophrenia, neurodevelopment and glycogen synthase kinase-3].
Nadri C; Kozlovsky N; Agam G
Harefuah; 2003 Sep; 142(8-9):636-42, 644. PubMed ID: 14518171
[TBL] [Abstract][Full Text] [Related]
13. Glycogen synthase kinase-3 as a key regulator of cognitive function.
Fan X; Zhao Z; Wang D; Xiao J
Acta Biochim Biophys Sin (Shanghai); 2020 Mar; 52(3):219-230. PubMed ID: 32147679
[TBL] [Abstract][Full Text] [Related]
14. Verbal memory.
Sumiyoshi T
Handb Exp Pharmacol; 2015; 228():237-47. PubMed ID: 25977085
[TBL] [Abstract][Full Text] [Related]
15. Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease.
Huang HC; Klein PS
Curr Drug Targets; 2006 Nov; 7(11):1389-97. PubMed ID: 17100579
[TBL] [Abstract][Full Text] [Related]
16. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
Avila J; Wandosell F; Hernández F
Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
[TBL] [Abstract][Full Text] [Related]
17. Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain.
Swatton JE; Sellers LA; Faull RL; Holland A; Iritani S; Bahn S
Eur J Neurosci; 2004 May; 19(10):2711-9. PubMed ID: 15147305
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase-3 as a therapeutic target for cognitive dysfunction in neuropsychiatric disorders.
O'Leary O; Nolan Y
CNS Drugs; 2015 Jan; 29(1):1-15. PubMed ID: 25380674
[TBL] [Abstract][Full Text] [Related]
19. PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease.
O' Neill C
Exp Gerontol; 2013 Jul; 48(7):647-53. PubMed ID: 23470275
[TBL] [Abstract][Full Text] [Related]
20. Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: role of GSK-3beta in adult brain.
Takashima A
J Pharmacol Sci; 2009 Feb; 109(2):174-8. PubMed ID: 19179803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
